CA
NZ
UK
AU
IND
US
…
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
GSK plc is a London-listed pharmaceutical company focused on prescription medicines, vaccines and a majority stake in ViiV Healthcare. Long-term growth drivers include vaccine demand, progress in a diversified R&D pipeline and the HIV portfolio. Its global footprint and broad revenue mix could support resilience and may appeal to investors seeking exposure to established pharma franchises.
Key risks include clinical or regulatory setbacks, patent expiries and generic competition, pricing and reimbursement pressure in major markets, and execution risks around R&D and integration; investors should monitor these factors.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 7401.00M | 3477.00M | 6064.00M | 5628.00M | 5442.00M |
| Minority interest | -573.00M | -376.00M | -380.00M | -665.00M | -711.00M |
| Net income | 5716.00M | 2575.00M | 4928.00M | 4921.00M | 4385.00M |
| Selling general administrative | 9088.00M | 11015.00M | 9385.00M | 8372.00M | 10975.00M |
| Selling and marketing expenses | - | - | 371.00M | - | - |
| Gross profit | 23698.00M | 21900.00M | 21252.00M | 19770.00M | 22511.00M |
| Reconciled depreciation | 2314.00M | 2551.00M | 2294.00M | 2147.00M | 2524.00M |
| Ebit | 8105.00M | 4124.00M | 6844.00M | 6433.00M | 6201.00M |
| Ebitda | 11883.00M | 6675.00M | 9138.00M | 8805.00M | 8786.00M |
| Depreciation and amortization | 3778.00M | 2551.00M | 2294.00M | 2372.00M | 2585.00M |
| Operating income | 7169.00M | 5662.00M | 6993.00M | 6433.00M | 6201.00M |
| Other operating expenses | 25498.00M | 25714.00M | 23335.00M | 22891.00M | 27913.00M |
| Interest expense | 701.00M | 644.00M | 775.00M | 879.00M | 784.00M |
| Tax provision | 1112.00M | 526.00M | 756.00M | 707.00M | 346.00M |
| Interest income | 56.00M | 60.00M | 48.00M | 31.00M | 28.00M |
| Net interest income | -633.00M | -603.00M | -735.00M | -826.00M | -756.00M |
| Income tax expense | 1112.00M | 526.00M | 756.00M | 707.00M | 346.00M |
| Total revenue | 32667.00M | 31376.00M | 30328.00M | 29324.00M | 34114.00M |
| Total operating expenses | 16529.00M | 16238.00M | 14259.00M | 13337.00M | 16310.00M |
| Cost of revenue | 8969.00M | 9476.00M | 9076.00M | 9554.00M | 11603.00M |
| Total other income expense net | 232.00M | -2185.00M | -929.00M | -805.00M | -759.00M |
| Discontinued operations | - | - | - | 10495.00M | 1069.00M |
| Net income from continuing ops | 6289.00M | 2951.00M | 5308.00M | 4921.00M | 5096.00M |
| Net income applicable to common shares | - | - | - | 14956.00M | 4385.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 61118.00M | 59463.00M | 59005.00M | 60146.00M | 79103.00M |
| Intangible assets | 16748.00M | 15515.00M | 14768.00M | 14318.00M | 30079.00M |
| Other current assets | 421.00M | 502.00M | 1553.00M | 7746.00M | 8556.00M |
| Total liab | 45095.00M | 46377.00M | 46210.00M | 50050.00M | 57761.00M |
| Total stockholder equity | 16377.00M | 13671.00M | 13347.00M | 10598.00M | 15055.00M |
| Other current liab | 2998.00M | 14844.00M | 13816.00M | 2595.00M | 958.00M |
| Common stock | 1349.00M | 1348.00M | 1348.00M | 1347.00M | 1347.00M |
| Capital stock | 1349.00M | 1348.00M | 1348.00M | 1347.00M | 1347.00M |
| Retained earnings | 10209.00M | 7796.00M | 7239.00M | 4363.00M | 7944.00M |
| Other liab | - | - | - | 10205.00M | 13519.00M |
| Good will | 7018.00M | 6982.00M | 6811.00M | 7046.00M | 10552.00M |
| Other assets | - | - | - | 6818.00M | 6894.00M |
| Cash | 3397.00M | 3870.00M | 2936.00M | 3723.00M | 4274.00M |
| Total current liabilities | 21391.00M | 21697.00M | 21068.00M | 22810.00M | 23670.00M |
| Current deferred revenue | - | 171.00M | 222.00M | - | 1557.00M |
| Net debt | 14323.00M | 13284.00M | 15082.00M | 17264.00M | 19899.00M |
| Short term debt | 3012.00M | 2517.00M | 2813.00M | 3952.00M | 3601.00M |
| Short long term debt | 2875.00M | 2181.00M | 2657.00M | 3785.00M | 3398.00M |
| Short long term debt total | 17720.00M | 17154.00M | 18018.00M | 20987.00M | 24173.00M |
| Other stockholder equity | 4819.00M | 3076.00M | 3163.00M | 4888.00M | 5764.00M |
| Property plant equipment | - | - | - | 9620.00M | 10672.00M |
| Total current assets | 17510.00M | 16997.00M | 18644.00M | 20769.00M | 18674.00M |
| Net tangible assets | - | - | - | -10766.00M | -25576.00M |
| Short term investments | 9.00M | 21.00M | 2246.00M | 4154.00M | 61.00M |
| Net receivables | 7759.00M | 6935.00M | 5905.00M | 5452.00M | 8346.00M |
| Long term debt | 14015.00M | 13703.00M | 14154.00M | 16194.00M | 19760.00M |
| Inventory | 5924.00M | 5669.00M | 5498.00M | 5146.00M | 5783.00M |
| Accounts payable | 15381.00M | 3462.00M | 3717.00M | 16263.00M | 17554.00M |
| Accumulated other comprehensive income | - | 1451.00M | 1597.00M | - | - |
| Non currrent assets other | 2148.00M | 898.00M | 634.00M | 5348.00M | 1755.00M |
| Non current assets total | 43608.00M | 42466.00M | 40361.00M | 39377.00M | 60429.00M |
| Capital lease obligations | 830.00M | 1102.00M | 1207.00M | 1008.00M | 1015.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 11.00M | -1229.00M | -1595.00M | -8772.00M | 334.00M |
| Change to liabilities | - | - | - | 494.00M | 284.00M |
| Total cashflows from investing activities | -5851.00M | -1229.00M | -1595.00M | -8772.00M | -1777.00M |
| Net borrowings | 1506.00M | -1166.00M | -2370.00M | -4824.00M | -2210.00M |
| Total cash from financing activities | -1629.00M | -4726.00M | -5641.00M | 823.00M | -7589.00M |
| Change to operating activities | - | - | - | -1425.00M | 1260.00M |
| Net income | 5716.00M | 2951.00M | 4928.00M | 4921.00M | 5096.00M |
| Change in cash | -473.00M | 545.00M | -567.00M | -394.00M | -1443.00M |
| Begin period cash flow | 3870.00M | 2858.00M | 3425.00M | 3819.00M | 5262.00M |
| End period cash flow | 3397.00M | 3403.00M | 2858.00M | 3425.00M | 3819.00M |
| Total cash from operating activities | 7303.00M | 6554.00M | 6768.00M | 7403.00M | 7952.00M |
| Issuance of capital stock | 15.00M | 20.00M | 10.00M | 25.00M | 21.00M |
| Depreciation | 3778.00M | 2551.00M | 2294.00M | 2298.00M | 2524.00M |
| Other cashflows from investing activities | 1492.00M | -1219.00M | 1238.00M | -3721.00M | 36.00M |
| Dividends paid | 2564.00M | 2444.00M | 2247.00M | 3467.00M | 3999.00M |
| Change to inventory | -140.00M | -294.00M | -424.00M | -269.00M | 25.00M |
| Change to account receivables | - | 340.00M | -649.00M | -158.00M | -782.00M |
| Sale purchase of stock | -1377.00M | 0.00M | -197.00M | - | -1643.00M |
| Other cashflows from financing activities | -586.00M | -1136.00M | -1034.00M | 8887.00M | 27.00M |
| Change to netincome | - | - | - | -8342.00M | 105.00M |
| Capital expenditures | 1348.00M | 2982.00M | 2344.00M | 2258.00M | 2931.00M |
| Change in working capital | -622.00M | 256.00M | -841.00M | 271.00M | -473.00M |
| Stock based compensation | 374.00M | 344.00M | 307.00M | 346.00M | 367.00M |
| Other non cash items | -1569.00M | 452.00M | 945.00M | -433.00M | 756.00M |
| Free cash flow | 5955.00M | 3572.00M | 4424.00M | 5145.00M | 5021.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
|
Stock Name
|
Change
(GBX) |
Price
(GBX) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GSK GSK plc |
8.50 0.44% |
1923.50 | 15.59 | 22.47 | 2.65 | 5.23 | 3.07 | 9.64 |
| AZN AstraZeneca PLC |
-32.00 0.25% |
12822.00 | 31.30 | 19.57 | 4.02 | 6.20 | 5.78 | 17.40 |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
| Name | Title | Year Born |
|---|---|---|
| Ms. Emma Natasha Walmsley | CEO & Director | 1970 |
| Mr. Iain James Mackay | CFO & Exec. Director | 1962 |
| Ms. Julie Brown | Chief Financial Officer | 1962 |
| Ms. Shobie Ramakrishnan | Chief Digital & Technology Officer | NA |
| Mr. Tony Wood | Chief Scientific Officer | NA |
| Ms. Sarah Elton-Farr | Head of Investor Relations | NA |
| Mr. James Ford | Sr. VP & Group Gen. Counsel of Legal & Compliance | NA |
| Ms. Sally Jackson | Sr. VP of Global Communications & CEO Office | NA |
| Ms. Diana Conrad | Chief People Officer | NA |
| Mr. David Simon Redfern | Chief Strategy Officer | 1966 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+2.10%
Communication Services
+1.48%
Consumer Cyclical
+2.12%
Consumer Defensive
+1.59%
Energy
-2.52%
Financial Services
+1.11%
Financials
-6.05%
Healthcare
+2.12%
Industrials
-0.12%
Real Estate
+1.25%
Technology
-0.07%
Utilities
+0.57%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...